Literature DB >> 12544489

Progress and limitations in cancer gene therapy.

Dae Seog Heo1.   

Abstract

This is a brief discussion on the progress of gene therapy and the limitations of present-day gene therapy clinical trials based on a review of 464 human trial protocols from the U.S. National Institutes of Health (NIH) and the U.S. Federal Drug Administration (FDA). The paper also discusses an aspect of the gene therapy research of the author, who, together with colleagues, conducted the first gene therapy clinical trial in Korea in 1995.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12544489     DOI: 10.1097/00125817-200211001-00011

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  2 in total

1.  Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene.

Authors:  Dujuan Cao; Qianqian Song; Junqi Li; Louisa S Chard Dunmall; Yuanyuan Jiang; Bin Qin; Jianyao Wang; Haoran Guo; Zhenguo Cheng; Zhimin Wang; Nicholas R Lemoine; Shuangshuang Lu; Yaohe Wang
Journal:  Mol Ther Oncolytics       Date:  2022-04-25       Impact factor: 6.311

Review 2.  Gene therapy for gastric cancer: is it promising?

Authors:  Andreas P Sutter; Henry Fechner
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.